Table 1 Characteristics of metastatic NSCLC patients
N | (%) | |
|---|---|---|
Age (yrs) | 58 years (range 29-76) | 100 |
Gender | ||
Male | 36 | 60 |
Female | 24 | 40 |
Performance status | ||
0 | 14 | 23.3 |
1 | 41 | 68.3 |
2 | 5 | 8.3 |
Histology | ||
Large-cell carcinoma | 8 | 13.3 |
Adenocarcinoma | 39 | 65 |
Squamous cell carcinoma | 13 | 21.7 |
Smoking history | ||
Current smoker | 22 | 36.7 |
Never smoked | 7 | 11.7 |
Former smoker | 20 | 33.3 |
Unknown | 11 | 18.3 |
Number of chemotherapy lines | ||
1 | 18 | 30 |
≥2 | 42 | 70 |
Metastatic site | ||
Lung | 25 | 41.7 |
Bone | 23 | 38.3 |
Brain | 10 | 10 |
Liver | 4 | 6.7 |
Pleura | 8 | 13.3 |
Adrenal | 8 | 13.3 |
Skin | 1 | 1,7 |
Others | 4 | 6.7 |
EGFR mutations (51 patients screened) | ||
del 19 | 7 | 13.7 |
L858R | 2 | 3.9 |
Total | 9 | 17.6 |
K-ras mutations (56 patients screened) | 10 | 17.8 |
First-line therapy | ||
Chemotherapy | 52 | |
Erlotinib | 7 | |
Chemotherapy + erlotinib | 1 | |
Response | ||
Complete response | 5 | 8.9 |
Partial response | 28 | 50 |
Stable disease | 5 | 8.9 |
Progressive disease | 13 | 23.2 |
Not measurable | 9 | 8.9 |